These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 34312372)

  • 1. Identification of a prognostic ferroptosis-related lncRNA signature in the tumor microenvironment of lung adenocarcinoma.
    Guo Y; Qu Z; Li D; Bai F; Xing J; Ding Q; Zhou J; Yao L; Xu Q
    Cell Death Discov; 2021 Jul; 7(1):190. PubMed ID: 34312372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel autophagy-related lncRNA survival model for lung adenocarcinoma.
    Wu L; Wen Z; Song Y; Wang L
    J Cell Mol Med; 2021 Jun; 25(12):5681-5690. PubMed ID: 33987935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a ferroptosis-related long noncoding RNA signature with a prognostic value in adrenocortical carcinoma.
    Wang W; Chang G; Zhuo R; Ye C
    Front Genet; 2022; 13():949457. PubMed ID: 36457749
    [No Abstract]   [Full Text] [Related]  

  • 4. A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma.
    Lu Y; Luo X; Wang Q; Chen J; Zhang X; Li Y; Chen Y; Li X; Han S
    Front Genet; 2022; 13():862741. PubMed ID: 35368663
    [No Abstract]   [Full Text] [Related]  

  • 5. Characterization and validation of a ferroptosis-related LncRNA signature as a novel prognostic model for lung adenocarcinoma in tumor microenvironment.
    Wang Y; Lu G; Xue X; Xie M; Wang Z; Ma Z; Feng Y; Shao C; Duan H; Pan M; Ding P; Li X; Han J; Yan X
    Front Immunol; 2022; 13():903758. PubMed ID: 36016939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of a Ferroptosis-Related Long Non-coding RNA Prognostic Signature and Competing Endogenous RNA Network in Lung Adenocarcinoma.
    Fei X; Hu C; Wang X; Lu C; Chen H; Sun B; Li C
    Front Cell Dev Biol; 2021; 9():751490. PubMed ID: 34820377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma.
    Fang X; Huang E; Xie X; Yang K; Wang S; Huang X; Song M
    Front Genet; 2022; 13():951311. PubMed ID: 36406130
    [No Abstract]   [Full Text] [Related]  

  • 8. A Novel lncRNA Panel Related to Ferroptosis, Tumor Progression, and Microenvironment is a Robust Prognostic Indicator for Glioma Patients.
    He Y; Ye Y; Tian W; Qiu H
    Front Cell Dev Biol; 2021; 9():788451. PubMed ID: 34950662
    [No Abstract]   [Full Text] [Related]  

  • 9. Characterization of a ferroptosis and iron-metabolism related lncRNA signature in lung adenocarcinoma.
    Yao J; Chen X; Liu X; Li R; Zhou X; Qu Y
    Cancer Cell Int; 2021 Jul; 21(1):340. PubMed ID: 34217273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and Validation of a Three Pyroptosis-Related lncRNA Signature for Prognosis Prediction in Lung Adenocarcinoma.
    Liu J; Liu Q; Shen H; Liu Y; Wang Y; Wang G; Du J
    Front Genet; 2022; 13():838624. PubMed ID: 35928454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and Validation of a Ferroptosis-Related Long Non-coding RNA Signature for Predicting the Outcome of Lung Adenocarcinoma.
    Zheng Z; Zhang Q; Wu W; Xue Y; Liu S; Chen Q; Lin D
    Front Genet; 2021; 12():690509. PubMed ID: 34367250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a ferroptosis-related long non-coding RNA signature for prognosis prediction of ovarian cancer.
    Gao J; Pang X; Ren F; Zhu L
    Carcinogenesis; 2023 May; 44(1):80-92. PubMed ID: 36300656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a RNA-Seq Based Prognostic Signature with Seven Immune-Related lncRNAs for Lung Adenocarcinoma.
    You J; Fang W; Zhao Q; Chen L; Chen L; Chen F
    Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a Ferroptosis-Related LncRNA Signature as a Novel Prognosis Model for Lung Adenocarcinoma.
    Lu L; Liu LP; Zhao QQ; Gui R; Zhao QY
    Front Oncol; 2021; 11():675545. PubMed ID: 34249715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and verification of a prognostic ferroptosis-related lncRNAs signature for patients with lung adenocarcinoma.
    Qi K; Liu XL; Chen XL; Song C; Peng JH; Xu JJ
    Am J Transl Res; 2022; 14(6):3698-3715. PubMed ID: 35836852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A New Ferroptosis-Related lncRNA Signature Predicts the Prognosis of Bladder Cancer Patients.
    Chen M; Nie Z; Li Y; Gao Y; Wen X; Cao H; Zhang S
    Front Cell Dev Biol; 2021; 9():699804. PubMed ID: 34869304
    [No Abstract]   [Full Text] [Related]  

  • 17. Development and validation of a prognostic risk signature for lung adenocarcinoma constructed by six ferroptosis, necroptosis, and pyroptosis-related lncRNAs.
    Peng L; Ji J; Zhang C; Wu Z; Sun Y; Fan K; Du W; Liu A; Jiao W
    J Thorac Dis; 2022 Oct; 14(10):3955-3974. PubMed ID: 36389299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a novel ferroptosis‑related lncRNA prognostic signature for pancreatic adenocarcinoma.
    Li J; Li W; Wang H; Ni B; Liu Y
    Mol Med Rep; 2023 Feb; 27(2):. PubMed ID: 36660936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and Validation of a Novel Ferroptosis-Related lncRNA Signature to Predict Prognosis in Colorectal Cancer Patients.
    Zhang W; Fang D; Li S; Bao X; Jiang L; Sun X
    Front Genet; 2021; 12():709329. PubMed ID: 34777458
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk stratification of lung adenocarcinoma using a nomogram combined with ferroptosis-related LncRNAs and subgroup analysis with immune and N6-methyladenosine modification.
    Gao C; Kong N; Zhang F; Tang T; Li J; Ding H; Sun Z; Wu L; Xu M
    BMC Med Genomics; 2022 Jan; 15(1):15. PubMed ID: 35093068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.